Ocuphire Pharma: A Clear Focus on Retinal and Refractive Eye Disorder
Join us for an insightful webinar on May 15th, as we delve into the forefront of ophthalmic innovation with Ocuphire Pharma's CEO, George Magrath.
In this exclusive session, we'll explore the latest advancements and strategic initiatives driving Ocuphire Pharma's mission to tackle retinal and refractive eye disorders head-on.
Don't miss out on this unique opportunity to gain valuable insights into the future of eye care.
George Magrath, MD, currently serves as Chief Executive Officer and a Board member of Ocuphire. Dr. Magrath is a board-certified ophthalmologist with extensive clinical, business, and financial experience. Most recently, Dr. Magrath was CEO of Lexitas Pharma Services, a leading contract research organization in ophthalmology. Lexitas experienced a substantial growth in headcount, expanded into multiple additional service offerings, including an image reading center and a significant shift into retinal diseases, and was acquired by a top-tier private equity group during Dr. Magrath's tenure. Prior to Lexitas, Dr. Magrath served as the medical director at Hovione, where the team he worked with was responsible for the development of proprietary assets in ophthalmology, dermatology, and respiratory. Dr. Magrath began his career as an equity analyst at Edison Investment Research where he covered small and mid-sized pharma and biotechnology companies. Dr. Magrath holds a Master of Applied Economics from Johns Hopkins University, a Master of Business Administration from The Citadel, and a Medical Degree from the Medical University of South Carolina.
About Ocuphire Pharma
Ocuphire Pharma, Inc. is a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing small-molecule therapies for the treatment of retinal and refractive eye disorders. Phentolamine is currently being developed in clinical trials for a number of refractive eye disorder indications in partnership with Viatris. Ocuphire's lead retinal product candidate, APX3330, is a first-in-class small-molecule inhibitor of Ref-1 (reduction oxidation effector factor-1 protein) in clinical development for diabetic retinopathy. APX3330 is not approved for use by any regulatory health authority in any country.
Date: November 22, 2023
Time: 9:00 PM BJT / 8:00 AM ET
Moderator: Marc Estigarribia, MD of MSQ Ventures
Can’t attend live? Register anyway, and we’ll send you the session recording after the event. Following the webinar, attendees will also have the chance to schedule a one-on-one session with BiOneCure through MSQ.